Obesity is a complex disease characterized by excessive fat accumulation which is caused
by genetic, environmental and other factors. In recent years, there has been an increase in …

The glucagon-like peptide-1 receptor agonist (GLP-1RA) semaglutide is the most recently
approved agent of this drug class, and the only GLP-1RA currently available as both …

The gastrointestinal tract—the largest endocrine network in human physiology—
orchestrates signals from the external environment to maintain neural and hormonal control …

The incretin hormone Glucagon-Like Peptide-1 (GLP-1) is best known for its “incretin effect”
in restoring glucose homeostasis in diabetics, however, it is now apparent that it has a …

Background The results of the ELIXA trial demonstrated the cardiovascular safety of
lixisenatide, a short-acting glucagon-like peptide-1 receptor agonist, in patients with type 2 …

Gut microbiota variances reflecting the severity type 2 diabetes mellitus (T2DM).
Achyranthes bidentata polysaccharide (ABP) can regulate gut microbiota. However, the …

This meta-analysis aimed to evaluate the efficacy and safety of glucagon-like peptide 1 (GLP-
1) receptor agonists for women with polycystic ovary syndrome (PCOS) by comparing their …

Objective To compare the efficacy and safety between and within glucagon-like peptide-1
receptor agonists (GLP-1RAs) and sodium-glucose cotransporter 2 inhibitors (SGLT-2is) in …

Aims/hypothesis This study aimed to investigate the acute renal effects of the glucagon-like
peptide-1 receptor agonist (GLP-1RA) exenatide in type 2 diabetes patients. Methods We …

The prevalence of “diabesity”–diabetes related to obesity–has increased tremendously over
the past few decades because of the global obesity epidemic. Although bariatric surgery is …